Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05989724 · ClinicalTrials.gov registry record · Phase 1

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

A Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by Qurgen.

Recruiting
Registry status
Phase 1
Development phase
150
Enrollment target
5
Study locations

NCT05989724 is a Phase 1 study of Breast Cancer and Colorectal Cancer that is actively recruiting participants, run by Qurgen. The registered enrollment target is 150 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05989724, a Phase 1 study of Breast Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Qurgen.

RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target
5
Study locations

Study Summary

This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors.

Conditions Studied

Breast Cancer Colorectal Cancer Ovarian Cancer Pancreatic Cancer Solid Tumor

Interventions

  • DRUG SON-DP

Study Locations (5)

Arizona

  • Banner MD Anderson Cancer Center (BMDACC) - Gilbert

Michigan

  • Henry Ford Health System - Detroit

North Carolina

  • Carolina BioOncology Institute - Huntersville

Oklahoma

  • Stephenson Cancer Center, University of Oklahoma - Oklahoma City

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2023-09-19
Est. Completion 2026-03
Phase Phase 1

Sponsor

Qurgen

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05989724

The ClinicalTrials.gov registry entry for NCT05989724 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Qurgen, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which SON-DP is the first listed.

NCT05989724 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, Michigan, North Carolina.

Frequently Asked Questions

What is clinical trial NCT05989724 about?

NCT05989724 is a clinical study titled "A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors". This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors.

What is the current status of trial NCT05989724?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2023-09-19. Estimated completion is 2026-03.

What conditions does trial NCT05989724 study?

This clinical trial studies the following conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor.

What interventions are being tested in trial NCT05989724?

The interventions under investigation include: SON-DP (DRUG).

Who is sponsoring clinical trial NCT05989724?

This trial is sponsored by Qurgen, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05989724 being conducted?

This trial has 5 study locations across Arizona, Michigan, North Carolina, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Colorectal Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.